Mesothelioma

Disease-a-Month

Volumn 57, Issue 1, 2011, Pages 40-54

  Fuhrer, Gregory ^a   Lazarus, Angeline A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; CISPLATIN; PEMETREXED;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; ENVIRONMENTAL EXPOSURE; HEREDITY; HUMAN; MESOTHELIOMA; MULTIMODALITY CANCER THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL HEALTH; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION EXPOSURE; RISK ASSESSMENT;

ASBESTOS; HUMANS; INHALATION EXPOSURE; MESOTHELIOMA; PLEURAL NEOPLASMS; PROGNOSIS;

EID: 79251646163     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.disamonth.2010.12.004     Document Type: Article

References (37)

1. Practice Guidelines in Oncology: Malignant Pleural mesothelioma 2010, National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
2. Ismail-Khan R., Robinson L.A., Williams C.C., et al. Malignant Pleural mesothelioma: a comprehensive review. Cancer Control 2006, 13(4):255-263.
3. Kamp D.W. Asbestos-induced lung diseases: an update. Transl Res 2009, 153(4):143-152.
4. Fishman's Pulmonary Diseases and Disorders 2008, McGraw-Hill Medical. 4th ed. A.P. Fishman (Ed.).
5. Reid A., de Klerk N., Ambrosini G., et al. The additional risk of malignant pleural mesothelioma in former workers and residents of Wittenoom with benign pleural disease or asbestosis. Occup Environ Med 2005, 62(10):665-669.
6. Luo S., Liu X., Mu S., et al. Asbestos related diseases from environmental exposure to crocidolite in Da-yao, China. I. Review of exposure and epidemiological data. Occup Environ Med 2003, 60(1):35-42.
7. Abratt R.P., Vorobiof D.A., White N. Asbestos and mesothelioma in South Africa. Lung Cancer 2004, 45(suppl 1):S3-S6.
8. Huncharek M. Non-asbestos related diffuse malignant mesothelioma. Tumori 2002, 88(1):1-9.
9. Cvitanovic S., Znaor L., Konsa T., et al. Malignant and non-malignant asbestos-related pleural and lung disease: 10-year follow-up study. Croat Med J 2003, 44(5):618-625.
10. Carbone M., Bedrossian C. The pathogenesis of mesothelioma. Semin Diagn Pathol 2006, 23(1):56-60.
11. Dogan A.U., Baris Y.I., Dogan M. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 2006, 66(10):5063-5068.
12. Hirvonen A., Tuimala J., Ollikainen T., et al. Manganese superoxide dismutase genotypes and asbestos-associated pulmonary disorders. Cancer Lett 2002, 178(1):71-74.
13. Kumar V., Cotran R.S., Robbins S.L. Robbins and Cotran: Pathologic Basis of Disease 2005, Elsevier Saunders, Philadelphia, PA. 7th ed.
14. Nowak A.K., Armato S.G., Ceresoli G.L., et al. Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group. Lung Cancer 2010, 70(1):1-6.
15. Armato S.G., Entwisle J., Truong M.T., et al. Current state and future directions of pleural mesothelioma imaging. Lung Cancer 2008, 59(3):411-420.
16. Gill R.R., Umeoka S., Mamata H., et al. Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes. AJR Am J Roentgenol 2010, 195(2):W125-W130.
17. Geisel F.L., Bischoff H., von Tengg-Kobligk H., et al. Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of non-invasive assessment, therapeutic follow-up, and possible predictor of improved outcome. Chest 2006, 129(6):1570-1576.
18. Ordonez N.G. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med 2005, 129(11):1407-1414.
19. Bhalla R., Siddiqui M.T., Mandish D., et al. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks. Diagn Cytopathol 2007, 35(6):342-347.
20. Schneider J., Hoffmann H., Deinemann H., et al. Diagnostic and prognostic value of soluble mesothelinrRelated proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 2008, 3(11):1317-1324.
21. Yasumitu A., Tabata C., Tabata R., et al. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol 2010, 5(4):479-483.
22. Rai A.J., Flores R.M., Mathew A., et al. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin Chem Lab Med 2010, 48(2):271-278.
23. Sculier J.P., Berghmans T., Meert A.P. Update in lung cancer and mesothelioma 2009. Am J Respir Crit Care Med 2010, 181(8):773-781.
24. Hanna A., Pang Y., Bedrossian C.W., et al. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. Diagn Cytopathol 2010, 38(4):264-269.
25. Metintas M., Metintas S., Ucgun I., et al. Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. Respir Med 2001, 95(10):829-835.
26. Nowak A.K., Francis R.J., Phillips M.J., et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res 2010, 16(8):2409-2417.
27. Kumas P., Mratzke R.A. Molecular prognostic markers in malignant mesothelioma. Lung Cancer 2005, 49(suppl 1):S53-S60.
28. Flores R.M., Pass H.I., Seshan V.E., et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008, 135(3):620-626.
29. Nakas A., Martin Ucar A.E., Edwards J.G., et al. The role of thorascopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2008, 33(1):83-88.
30. Rice D.C., Stevens C.W., Correa A.M., et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007, 84(5):1685-1693.
31. Gupta V., Mychalczak B., Krug L., et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2005, 63(4):1045-1052.
32. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(14):2636-2644.
33. Krug L.M., Pass H.I., Rusch V.W., et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009, 27(18):3007-3013.
34. de Perrot M., Feld R., Cho B.C., et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009, 27(9):1413-1418.
35. Buduhan G., Menon S., Aye R., et al. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 2009, 88(3):870-876.
36. Castagneto B., Zai S., Mutti L., et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients. Lung Cancer 2001, 31(2-3):303-310.
37. Takemura Y., Satoh M., Satoh K., et al. High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem Biophys Res Commun 2010, 394(2):249-253.